High-protein Oral Supplement With Liposomal Curcumin in Adults Undergoing Hemodialysis.
Phase 3
Completed
NCT06381076
| Condition | Chronic Kidney Disease 5D |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | University of Florida |
|---|
| Status | Completed |
|---|
| Enrollment | 39 participants |
|---|
| Interventions | Liposomal curcumin, Food colorant |
|---|
| Start date | Feb 3, 2025 |
|---|
| Completion date | May 13, 2025 |
|---|
| Results posted | Jun 1, 2026 |
|---|
Summary
A 12-week double-blind randomized control trial will be conducted among adults on hemodialysis (n=15) to determine the impact of liposomal curcumin in a high-protein product on inflammation markers and oxidative stress. Participants will be randomized via a computer-generator into either the control or intervention group. Participants in each group will be given a total of 38 g of a high protein product with or without 7 mls of liposomal curcumin for a total of 8 weeks. At baseline, weeks 8 and 12, participants will have blood sampled and complete a 3-day 24-hour recalls (2 non-dialysis days and 1 dialysis day) and a quality of life survey.
High-sensitivity C-reactive Protein
12 weeks or 84 days · milligrams per liter (mg/L)
| Intervention | -1.39 ± 2.65 milligrams per liter (mg/L) |
|---|
| Control | 5.09 ± 2.43 milligrams per liter (mg/L) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
Other trials for this condition
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.